运动处方应用于非酒精性脂肪性肝病患者治疗作用和安全性评价

doi:10.3969/j.issn.1672-5069.2020.03.015

Abstract

Abstract: Objective The aim of this study was to explore the efficacy and safety of exercise prescription in the treatment of patients with nonalcoholic fatty liver disease (NAFLD). Methods A total of 59 patients with NAFLD were recruited in this study, and were randomly divided into exercise-intervened (n=33) and control group (n=26). The patients with NAFLD in the intervention group were givenexercise prescription with aerobic exercise and resistance movement, and those in the control were not. Results At the end of three-month intervention, the body weights, body mass index, whole body fat contents and waist circumferences in patients with NAFLD in the exercise-intervened group were from (81.9±10.4) kg, (28.5±2.4)kg/m², (25.4±4.9)kg and (92.2±6.5)cm decreased to , and the controlled attenuation parameter decreased from (281.5±15.4)dB/m through , while those parameters didn’t changed significantly in the control. Conclusion Our preliminary studies suggest that exercise prescription is safe, efficacious and tolerable in patients with NAFLD.

Key words: Nonalcoholic fatty liver disease, Exercise prescription, Aerobic exercise, Resistance movement, Controlled attenuation parameter

Zhang Yanan, Fan Zhuping. Efficacy and safety evaluation of exercise prescription in the treatment ofpatients with nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2020, 23(3): 360-363.

References

[1] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol, 2017, 67(4):862-873.
[2] 苏淑婷,钟燕,宓余强.非酒精性脂肪性肝病分级分期管理研究进展.实用肝脏病杂志,2019,22(2):293-296.
[3] Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol ,2017, 67(4):829-846.
[4] Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol,2017, 66(1):142-152.
[5] Chen Y, Xu M, Wang T, et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis, 2015, 241(1):145-150.
[6] Chang YK, Chu CH, Chen FT, et al. Combined effects of physical activity and obesity on cognitive function: independent,overlapping, moderator, and mediator Models. Sport Med, 2017, 47(3):449-468.
[7] Fealy CE, Haus JM, Solomon TP, et al. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol, 2012, 113(1):1-6.
[8] Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol, 2007, 22(6):775-777.
[9] Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010, 18:163-166). J Dig Dis,2011, 12(1):38-44.
[10] Croci I, Coombes JS, Bucher Sandbakk S ,et al. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behavior and cardiorespiratory fitness. The HUNT Study. Prog Cardiovasc Dis,2019, 62(2):127-134.
[11] Lavie CJ, Ozemek C, Carbone S, et al. Sedentary behavior, exercise, and cardiovascular health. Circul Res, 2019, 124(5):799-815.
[12] Malaguti C. Critical power for the upper limb in patients with chronic obstructive pulmonary diseases: a pilot study. Respir Physiol Neurobiol, 2019,42:103280.
[13] Fiuza-Luces C, Santos-Lozano A, Joyner M, et al. Exercise benefits in cardiovascular disease: beyond attenuation of traditional risk factors. Nat Rev Cardiol ,2018, 15(12):731-743.
[14] Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabet Care ,2016, 39(11):2065-2079.
[15] Singleton JR, Marcus RL, Lessard MK, et al. Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol, 2015, 77(1):146-153.
[16] Cheng S, Ge J, Zhao C, et al. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial. Scient Rep, 2017, 7(1):15952.
[17] Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metab Clin Experiment, 2017, 68:119-132.

Efficacy and safety evaluation of exercise prescription in the treatment ofpatients with nonalcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wu Pengbo, Song Qi, Yu Yuanjie, et al.. Effect and underlying mechanism of curcumin on oleic acid-induced steatosis of HepG2 cells in vitro [J]. Journal of Practical Hepatology, 2020, 23(3): 324-327.
[2]	Tang Xiaofei, Zhong Mengju, Shen Haijuan. Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats [J]. Journal of Practical Hepatology, 2020, 23(3): 328-331.
[3]	Tang Xinya,Hou Sen,Jiao Yingying. Effect of captopril on steatosis of hepatocytes in rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(3): 332-335.
[4]	Jiang Jiali, Li Li, Zhao Fei, et al. Expression of Vaspin in HepG2 cells and in liver tissues of rats with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 167-170.
[5]	Ye Xiaoxian, Yang Li, Lei Li. Predictive value of serum glycosylated hemoglobin and IL-6levels on the risk of nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2020, 23(2): 199-202.
[6]	Jia Chen, Zhang Tao, Wang Hao, et al. Efficacy of liraglutide in treatment of patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(2): 203-206.
[7]	Liu Jiguo, Dou Cuiyun , Cheng Guangling. Changes of blood glycosylated hemoglobin and thyroid hormone levels in patients with NAFLD complicated by T2DM [J]. Journal of Practical Hepatology, 2020, 23(2): 207-210.
[8]	Ren Guoliang, Li Liansheng, Liu Gang, et al. Improvement of insulin resistance, lipid profile and oxidative stress index by calorie restriction diet in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2020, 23(2): 219-222.
[9]	Chen Lili, Fu Maoxiong, Meng Xubiao, et al. Clinical value of fasting C-peptide in assessing the progression of liver fibrosis in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2020, 23(1): 38-41.
[10]	Mao Chongshan, Yin Hui, Xiao Erhui, et al. Effects of fenofibrate on blood lipids, vascular endothelial functions and liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2020, 23(1): 50-53.
[11]	Luo Qingling, Zhou Yongjian, Tang Wenjuan, et al. Effects of fecal bacteria transplantation on microflora in rats with high-fat-induced liver steatosis [J]. Journal of Practical Hepatology, 2020, 23(1): 134-137.
[12]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[13]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[14]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[15]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.